ASX Runners of the Week: Eden, Focus Minerals, InFocus & Dateline
The company's shares bounced back from a lowly 0.15c per share close last week to trade at 0.5c per share on Friday, up 333 per cent, on nearly $1 million of paper traded across two days.
Eden's star carbon nanotube-enriched concrete additive, EdenCrete, is shaking up the increasingly green concrete industry by boosting batch strength while slashing the need for carbon-heavy ordinary Portland cement.
A major win came with a $141,000 order from Holcim US for a 22-storey high-rise in Denver, which is Eden's first big-ticket commercial project.
The market lapped it up, with shares surging on Eden's green concrete breakthrough into high-rise buildings, one of the biggest addressable markets.
Meanwhile, Eden's OptiBlend dual-fuel kit, which lets diesel generators run cleaner on natural gas, continues to hum in the background, fuelling company sales across the US and India.
With concrete giants such as Holcim jumping on board and sales breaking into the mammoth high-rise building industry, Eden looks poised to cement its place as a clean tech leader. If its momentum holds, the company could go from market battler to skyscraper-high regular in quick succession.
FOCUS MINERALS (ASX: FML)
up 161% (23c – 60c)
Bulls N' Bears' silver medallist this week is Western Australian gold miner Focus Minerals, which shot up like a prospector's pickaxe on Tuesday thanks to a juicy $250M cash deal to offload its Laverton gold project to $5 billion market darling Genesis Minerals.
Punters were left scrambling to pick up shares in the cashed-up gold miner on Monday, with a whopping $5.2M traded to push the company's shares up 161 per cent to 60c per share.
Nestled in WA's prolific Leonora-Laverton district, the Laverton project is a stone's throw from Genesis' massive 3-million-tonne per annum Laverton mill.
The acquisition looks like a perfect fit for Genisis and is set to churn out ample tonnages of open pit and underground gold ore for the company's hungry mill.
The deal contains no pesky conditions precedent and is set to seal in early June, handing Focus a mountainous $250M in cash, which looks very timely considering the company is lugging around $187M in debt.
Focus will retain its producing Coolgardie gold project, where it cracked a record mining output in the past quarter. Its Three Mile Hill mill processed a thumping 370,262 tonnes for a handy 5376 ounces of gold at $4388 per ounce.
With its Bonnie Vale underground mine ahead of schedule and its Alicia open pit firing up, Focus could be hitting its straps in no time, as it looks to increase its lower-grade gold ore with higher-grade output from the newer mines.
Laverton's synergistic sale sent Focus' shares flying as investors bet on the company's cash windfall to turn its luck around in a red-hot gold price environment. With Coolgardie's Bonnie Vale underground cranking out ore and a new 80-room camp to house its growing crew, Focus is sitting pretty to join the mid-cap success stories of WA's gold sector – aided by its newfound financial flexibility.
INFOCUS GROUP HOLDINGS (ASX: IFG)
up 140% (0.5c – 1.2c)
Taking out the final podium spot on Runners of the Week is digital solutions experts InFocus Group, which shot out of a cannon on Tuesday by unveiling a blockbuster US$3.25M (A$5M) deal to become the exclusive tech partner for Taiwanese gaming guru TG Solutions Consulting.
A feeding frenzy ensued with the company's share price rocketing 140 per cent to 1.2c per share on a sizzling $1.2M in stock traded. This was nearly as much as the entire company's preannouncement market valuation of $1.3M.
InFocus says it is set to build a cutting-edge iGaming platform for TG's white-label distribution. It promises to be packed with bells and whistles, such as a polymarket-inspired dynamic odds system, digital collectibles, tokenised loyalty programs and crypto payments.
The contract includes milestone-based payments and locks in InFocus as TG's go-to tech partner for all future rollouts. The company says it's a growing market trend as predictive gaming evolves thanks to big data, analytics and cybersecurity expenditure.
Investors would seem to agree, betting big on InFocus's pivot into the red-hot iGaming sector. With trials wrapping up and the platform set to launch within two years, the company looks well-positioned at the forefront of a digital gaming revolution that might return the market minnow to its former glory.
DATELINE RESOURCES (ASX: DTR)
up 86% (5.5c – 10.25c)
Finally, Dateline Resources has hit the Runners list for the third time in almost as many weeks. Attempting its best 'broken record' impersonation and continuing to break its share price highs, the US-based junior goldie's share price has risen an eye-watering 1950 per cent this quarter and shows no signs of slowing down.
The company's shares peaked on Friday at 10.25c, up 86 per cent over the week, on a monumental $80M in shares traded.
Following Trump's Truth Social championing of the company's 'rare earths mine' earlier this month, Dateline continued its breakout on Tuesday when it told the market its Colosseum project in California could be sitting on a much larger gold system than previously realised.
A recent rock chip program picked up several outcropping felsite dykes up 1 kilometre west and 4km southwest of the existing pit, which appear to follow a deliberate geological trend.
Adding fuel to the fire, results of a fresh surface geochemical survey now point to concealed breccia pipes lurking just beyond the rim of the mine's historic pits.
The company says the new mineralisation lines up like clockwork with its known structural gold system and could point to a string of satellite intrusions which, if confirmed, could unearth even more gold-rich breccia pipes brewing just below the surface.
The latest rock samples lit up with classic pathfinder elements such as antimony, bismuth and tellurium, which are textbook signs of an intrusion-related gold system. These IRGS-style systems are known for their layered structure, with lighter elements floating near the surface and the real prize - gold - tending to settle deeper.
Armed with a fresh trail of geological breadcrumbs, Dateline is ramping up for its next big move. More surface sampling is underway, and the company is locking in its first drilling campaign beyond the pit walls. The program will chase the projected path of the newly mapped felsite dykes and test if the Colosseum's breccia pipes are just the tip of a much bigger, vertically stacked golden iceberg.
If the upcoming drill campaign strikes more gold, it could blow the doors open on Dateline's already impressive 1.1-million-ounce resource and unlock a whole new chapter of potential at Colosseum.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 hours ago
- News.com.au
Biocurious: Inspired by Neuren, Nyrada aims to change the treatment landscape for brain and heart disorders
Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injury Preclinical work has shown a significant reduction in secondary brain injury and cardiac damage CEO James Bonnar spent 15 years at Neuren Pharmaceuticals in the company's formative stage Nyrada (ASX:NYR) CEO James Bonnar is too modest to admit it, but he played a key role in developing and commercialising Neuren Pharmaceuticals' (ASX:NEU) neurological drug Daybue. Bonnar was one of the then New Zealand-based Neuren's first employees and spent a decade at the company, which now bears a $1.7 billion market cap. Bonnar seeks to channel Neuren's virtues as Nyrada pursues small molecule treatments for both brain and heart protection. Before Neuren, Bonnar was with Protemix, which worked on a drug for diabetes-related cardiomyopathy. 'This is not my first rodeo." Nyrada's indications of interest include traumatic brain injury (TBI), which Neuren pursued before switching development to the childhood disorder Rett syndrome. 'You learn a lot of lessons along the way, competing in both successful and unsuccessful programs,' Bonnar says. Have a nice TRPC Nyrada's lead drug was called NYR-BI03, but last week the company bestowed the 'proper' name of Xolatryp to reflect the drug's 'advancing development'. The science is based on bodily transient receptor potential canonical (TRPC) ion channels (often pronounced 'tripsy'). These conduits regulate calcium influx into cells. 'Following ischemia or injury, these ion channels are activated and let in calcium into the cell,' Bonnar says. 'That calcium builds up to the extent where they're toxic.' As with Neuren, Nyrada had a spare clinical program in its back pocket. The Delaware-incorporated Nyrada listed in 2020, having spun off from immunology play Noxopharm (ASX:NOX). Nyrada initially focused on oral inhibitors which failed preclinical toxicology studies. 'Fortunately, we had a promising secondary program, which is now the lead program," Bonnar says. Xolatryp blocks TRPC channels to protect key cells in vital organs when under stress. In the case of brain neurons, that could be after ischaemia (a blood clot) and reperfusion (the sudden flow of blood returning to an organ or tissue). Ischemic-reperfusion injury is also a key cause of tissue damage following the restoration of blood flow to the heart post-injury. It's a knock-out! Using a 'knock out' mice model, pioneering work at the University of NSW (Uni NSW) showed the rodents were protected from stroke. The 'knock out' doesn't refer to concussing the critters with a mallet, but genetically modifying and cross breeding them so they no longer express the TRPC channels. 'This confirmed that completely knocking out the channel is safe and for all intents and purposes these mice lived a normal life,' Bonnar says. Over the last 12 months, Nyrada has focused on expanding efficacy data that builds on this 'knock out' mouse work. 'We went through a few iterations of molecules that showed promise, but they weren't target specific,' Bonnar says. Let's get clinical Preclinical work suggests Xolatryp is delivering significant reduction in secondary brain injury and cardiac damage For cardiac reperfusion, rat models showed an 86% reduction in injury (there are no other approved treatments). With ischemic strokes, a mouse study showed 42% protection. The company also ran a neuroprotection study with the Walter Reed Army Institute Research and Uni NSW, deploying a TBI model. Based on follow-up magnetic resonance imaging, this showed a 'statistically significant' neuroprotective benefit. Now for a human study As they say, everything works in mice … or rats. Nyrada's attention now has turned to a phase I healthy volunteer study to appraise dosing safety. The randomised, double blinded effort involves three-hour infusions, compared with 20 hours for the first preclinical study. The study consists of three eight-patient cohorts, six on the active drug and two on the placebo in each group. Bonnar says the trial will guide the company on what indication to pursue in a phase II study. 'In each one, there is first-in-class potential with large markets and unmet need.' The company is hoping to complete the study in September. Later, the company also would like to run a TBI study in the US, given the large addressable population. 'You would struggle to do that in Australia,' Bonnar says. Tackling a barren treatment landscape Bonnar describes Xolatryp as a 'Swiss Army knife' drug candidate, in that it could have broad uses. He says the current TBI treatments only alleviate the symptoms, rather than the condition. 'It's a similar situation with ischaemic stroke, but not quite so bad.' While clot-busting drugs work effectively, they need to be administered in a narrow time window (the 60 minutes after a stroke is called the Golden Hour). Given that, they only apply to 10-15% of patients. As for cardio protection, existing drugs can reduce the ticker's workload after a heart attack, but none of them protects the heart tissue. Can Nyrada 'do a Neuren?' Despite Xolatryp's snazzy name, Nyrada faces many years and development dollars before it 'does a Neuren'. Of course, most drug developers tripsy-up before reaching the end game. Bonnar dubs TRPC as a 'hot' research area reflected in Nyrada's share price: up 68% over the last month and 160% over the last year, ascribing a $38 million market cap. 'Big Pharma is looking at cardio protection in particular and we think our novel molecule … should attract interest,' Bonnar says. At the end of March Nyrada had $4.7 million of cash, enough to fund the phase I study. 'We are pretty lean; we work as a virtual company with a low head count.' Bonnar notes Boehringer Ingelheim has developed a TRPC inhibitors for renal fibrosis, while elsewhere work is afoot to develop one for the chronic condition of cardiac hypertrophy. 'But as far as I'm aware, we are the first company to be looking at a TRPC channel blocker in the clinic in our chosen indications.'
AU Financial Review
4 hours ago
- AU Financial Review
ASX to rise, Nvidia helps pace Wall St higher
Australian shares are set to open higher, tracking a solid session in New York after data showed that the US jobs market is holding steady. Nvidia and Broadcom paced semiconductor shares higher. President Donald Trump is poised to sign a directive formally raising steel and aluminium tariffs to 50 per cent from 25 per cent on Wednesday AEST. There has been a 'tremendous return' to 'basic rational investing' this year, AQR Capital Management's Cliff Asness told Bloomberg. 'The market has rewarded good companies that are getting better, that aren't too risky. We are not in a bubble.' Broadcom hit a fresh record high after the company said it has begun to ship its latest networking chip that aims to speed AI. Its shares were up 2.5 per cent. Nvidia advanced 2.7 per cent extending a rebound from its April low to more than 45 per cent. Market highlights ASX futures are pointing up 27 points or 0.3 per cent to 8511. All US prices are as of 2.30pm New York time. Today's agenda The key focus will be the release of first-quarter GDP data at 11.30am. Overseas, a raft of May monthly services data will be released in Europe and the US. The Federal Reserve will release its latest Beige Book report early Friday AEST. Ahead of that, the Bank of Canada is expected to hold its key rate steady as policymakers await more clarity around tariff impacts. Top stories 'Adults in the room': Australia and EU push for trade deal | Australia and the EU have redoubled efforts to secure a free trade agreement as insurance against Donald Trump's trade war. | Nearly half the $93 billion superannuation fund's investment governance team was considering quitting within two years, confidential data shows. | The OECD has urged the federal and state governments to repair their budgets, as new data shows record growth in welfare spending and business investment languishes. Japan's Mixi hikes PointsBet takeover bid, valuing bookmaker at $402m | The entertainment giant's hopes of acquiring the ASX-listed group had been complicated by a rival proposal from Matthew Tripp's Betr, which holds 20 per cent.
News.com.au
14 hours ago
- News.com.au
Closing Bell: ASX powers to new 50-day high, up 0.63pc
ASX adds 52 points, hitting a new 50-day high at 8,466.70 points Broad strength with 9 of 11 sectors on the up Gold and finance stocks outperform The ASX was on a roll today, climbing swiftly in the first hour of trade and maintaining momentum throughout trade to finish up by 0.63%. That also marks a new 50-day high for the bourse, which is just 1.72% off the all-time highs reached in February this year. All but two sectors made convincing gains today, with just Consumer Discretionary (-0.11%) and Health Care (-0.37%) lagging. The ASX All Ords Gold Index outperformed once again, surging 2.46% on another lift in gold prices, which climbed 2.5% to US$3397.20 an ounce overnight. The ASX 200 Banks index also stood out, jumping 1.3%. The major four banks gained between 1.19% and 1.37%. RBA outlines tariff risks for Australian economy Speaking to the Economic Society of Australia in Brisbane today, RBA assistant governor Sarah Hunter opened with a quote from Lenin. 'There are decades where nothing happens; and there are weeks where decades happen'. It certainly feels like we've been in the tariff war trenches for years at this point, although in truth this all kicked off just four months ago. 'The broad-based nature of the proposed US tariffs, retaliation from major partners and other policy shifts all have the potential to structurally alter the world economy,' Hunter continued. The RBA has identified the key transmission channels these structural changes will flow through: Realigning trade flows between countries, production shifting to new countries over time Tariffs are likely to change consumption habits as some products become more expensive Business and consumers will become more cautious in the face of flipflopping policy, delaying major decisions involving capital investment Hunter points out that both fiscal and monetary policy can be adjusted to help offset adverse effects, and that financial markets will simply reprice assets. You can read her full speech (with sourcing and data analysis) on the RBA website, but in short Hunter concludes that we're in for a period of slower economic growth and a slightly weaker labour market. 'We also anticipate that, overall, the price of tradable goods will be slightly dampened,' Hunter said. 'Together, these two outcomes mean that inflation is forecast to be a little lower than at the February SMP, settling around the midpoint of the 2–3% target range.' While that's not good news, it's not cataclysmic either. The RBA says it will be watching its transmission channels closely from here on out, ready to adjust policy accordingly. ASX SMALL CAP LEADERS Today's best performing small cap stocks: Security Name Last % Change Volume Market Cap EPM Eclipse Metals 0.015 200% 65692044 $14,329,095 VAR Variscan Mines Ltd 0.007 40% 92864 $3,914,289 G88 Golden Mile Res Ltd 0.018 38% 10828150 $7,075,222 BYH Bryah Resources Ltd 0.015 36% 42903096 $9,569,489 BMO Bastion Minerals 0.002 33% 1803250 $1,355,441 TYX Tyranna Res Ltd 0.004 33% 2483000 $9,865,276 BCA Black Canyon Limited 0.079 30% 630241 $7,908,692 NC1 Nicoresourceslimited 0.093 27% 412715 $8,008,142 WCE Westcoastsilver Ltd 0.078 26% 5130855 $16,127,501 CAV Carnavale Resources 0.005 25% 1133878 $16,360,874 EVR Ev Resources Ltd 0.005 25% 729920 $7,943,347 GLA Gladiator Resources 0.01 25% 884127 $6,066,375 MEM Memphasys Ltd 0.005 25% 499000 $7,934,392 UNT Unith Ltd 0.01 25% 2621527 $9,830,283 WMG Western Mines 0.195 22% 65152 $14,456,535 FTL Firetail Resources 0.091 21% 4345928 $28,502,098 BTM Breakthrough Minsltd 0.12 20% 348895 $4,785,950 ALY Alchemy Resource Ltd 0.006 20% 909133 $5,890,381 AN1 Anagenics Limited 0.006 20% 100000 $2,481,602 BIT Biotron Limited 0.003 20% 2444305 $3,318,115 GGE Grand Gulf Energy 0.003 20% 439921 $7,051,062 GLL Galilee Energy Ltd 0.006 20% 416 $3,535,964 ION Iondrive Limited 0.024 20% 15264360 $23,656,727 NES Nelson Resources. 0.003 20% 2700000 $5,429,819 PRX Prodigy Gold NL 0.003 20% 5693864 $7,937,639 Making news… Eclipse Metals (ASX:EPM) unveiled a massive 89 million tonne rare earths resource at its Grønnedal project in southwest Greenland. The updated estimate shows grades averaging over 6,300ppm TREO, including high-value magnet metals like neodymium, praseodymium, dysprosium and terbium – key ingredients for EVs and wind turbines. That puts it among the highest-grade rare earth deposits in the world. This new figure is more than 70 times bigger than the previous estimate, and the mineralisation still looks to extend in every direction, said EPM. Western Yilgarn (ASX:WYX) has snapped up the Cardea 3 Bauxite Project in WA's Darling Range, just 17km from its big Julimar West deposit. It paid a modest $5k upfront, and will tip in more cash and shares once the exploration licence is granted. Previous drilling at Cardea 3 shows high-grade bauxite, with standout results like 7.5m at over 48% total alumina and low reactive silica. Nico Resources (ASX:NC1) has received firm commitments for a $1.1m placement at an 11.4% premium to its 20-day VWAP. The funding will go to exploration and development of the Wingellina nickel-cobalt project, host to 40,000t of nickel and 3000t of cobalt. Sunshine Metals (ASX:SHN) has hit bonanza-grade gold mineralisation at the Liontown prospect, with results up to 10 metres at 31.91g/t gold from 41 metres of depth. With a smaller hit of 2 metres at 121.5g/t gold in hand, SHN says the results demonstrate the historical gold mine still hosts high-grade gold mineralisation, reinforcing the company's plans to pursue shallow oxide gold production. Alchemy Resources (ASX:ALY) has taken full ownership of the Bryah iron ore project, acquiring the remaining 50% interest from Carey Mining Pty Ltd for $75,000 cash and a royalty. The gradational royalty is based on iron ore prices sold FOB from the project, ranging from $0.80 per tonne at under US$100/t of iron ore and up to $1.22 should iron prices rise above US$125/t. The gold signal is coming in loud and clear from Solstice Minerals' (ASX:SLS) Bluetooth gold prospect, part of the Yarri gold project in WA. The company has hit multiple broad intersections from less than 50 metres below surface, grading up to 20m at 2.18g/t gold. ASX SMALL CAP LAGGARDS Today's worst performing small cap stocks: Security Name Last % Change Volume Market Cap BMH Baumart Holdings Ltd 0.011 -67% 674614 $5,419,086 ADD Adavale Resource Ltd 0.001 -50% 400000 $4,574,558 OB1 Orbminco Limited 0.001 -50% 81733 $4,795,136 MGU Magnum Mining & Exp 0.005 -33% 4155608 $8,412,381 OVT Ovanti Limited 0.002 -33% 8085945 $8,380,545 RCM Rapid Critical 0.002 -33% 7719243 $3,734,834 VML Vital Metals Limited 0.002 -33% 2815666 $17,685,201 BNL Blue Star Helium Ltd 0.006 -25% 12656652 $21,559,082 MTB Mount Burgess Mining 0.003 -25% 492539 $1,406,811 NAE New Age Exploration 0.003 -25% 4402993 $10,637,596 RAN Range International 0.0015 -25% 98459 $1,878,581 UBI Universal Biosensors 0.032 -24% 841535 $12,518,832 EVEDA EVE Health Group Ltd 0.023 -23% 889655 $3,955,862 OSLDA Oncosil Medical 0.95 -21% 14356 $13,819,740 CYQ Cycliq Group Ltd 0.002 -20% 336928 $1,151,292 EV1 Evolutionenergy 0.008 -20% 2240267 $3,626,505 IMI Infinitymining 0.008 -20% 180000 $4,230,158 IS3 I Synergy Group Ltd 0.004 -20% 10000 $2,503,651 MML Mclaren Minerals 0.026 -19% 300161 $4,528,561 EXT Excite Technology 0.009 -18% 3170658 $22,799,061 HT8 Harris Technology Gl 0.009 -18% 202841 $3,618,617 CRI Criticalim 0.019 -17% 47468447 $62,041,318 ADG Adelong Gold Limited 0.005 -17% 10842256 $8,384,917 AJL AJ Lucas Group 0.005 -17% 7861 $8,254,378 ARV Artemis Resources 0.005 -17% 3120042 $15,171,176 LAST ORDERS Titanium Sands (ASX:TSL) has finalised a corporate funding solution for the Mannar heavy mineral project, whereby CPS Capital Group will provide up to $600,000 in loan funding in two tranches. The funding will be used to finalise environmental studies, advance an industrial mining licence for the project, and for general working capital. ADX Energy (ASX:ADX) has tapped David Gilbert as non-executive director, replacing John Begg as he steps down from the board of directors. Gilbert has held senior positions in companies based in Austria and Romania, locations highly relevant to ADX's operations as the company holds projects in both countries. IN CASE YOU MISSED IT MTM Critical Metals' (ASX:MTM) has achieved 98% recovery of antimony from US e-waste using its proprietary Flash Joule Heating technology. Lumos Diagnostics (ASX:LDX) has enrolled 61 of required 120 bacterial positive patients in US CLIA waiver clinical study for its point-of-care respiratory test FebriDx, designed to differentiate between bacterial and non-bacterial acute respiratory infections. Sampling at Perpetual Resources' (ASX:PEC) Igrejinha lithium project has uncovered more mineralisation ahead of RC drilling starting on June 5. essential projects unfulfilled by banks and government. Leeuwin Metals (ASX:LM1) has started phase 2 drilling at its Marda gold project to follow-up on high-grade gold intersected in the phase 1 program. Lithium Universe (ASX:LU7) is pursuing a non-binding MoU to cover full annual SC6 spodumene supply of 140,000 tonnes for its Bécancour lithium refinery in Canada. Health technology company Cardiex (ASX:CDX) has achieved an important milestone, receiving Therapeutic Goods Administration (TGA) approval for its CONNEQT Pulse arterial health monitor. Exploration is underway at Core Energy Minerals' (ASX:CR3) Grande Project in Rio Grande do Sul, Brazil, where broad uranium anomalism has been identified at surface. With gold on a bull run, Codrus Minerals (ASX:CDR) has mobilised a diamond drilling rig to investigate five targets at its Bull Run gold project in the US. Cannindah Resources' (ASX:CAE) rock chip sampling has identified two untested copper-gold porphyry targets at Mt Cannindah, with assays up to 12.28% copper and 9.94g/t gold. Everest Metals' (ASX:EMC) has delivered an engineering scoping study for rubidium extraction through a partnership with Edith Cowan University. With gold prices booming, Artemis (ASX:ARV) is lining up the drills to grow its 374,000oz gold, 64,000t copper Carlow project, with 5000 metres planned in total. Western Yilgarn (ASX:WYX) has acquired the Cardea 3 bauxite project in WA's Darling Range, which has strong potential to further increase bauxite tonnage and grade through exploration. TRADING HALTS At Stockhead, we tell it like it is. While Titanium Sands and ADX Energy are Stockhead advertisers, they did not sponsor this article.
